$SRPT

President Trump may fire FDA Commissioner Marty Makary, according to the Wall Street Journal. Several biotech and pharmaceutical companies, including Replimune (REPL), uniQure (QURE), Moderna (MRNA), and others, have publicly clashed with the FDA over drug-review processes. Shares of REPL, QURE, and MRNA rose 17%, 15%, and 10% respectively at the time of writing.

Sarepta Therapeutics' INSIGHTT trial has begun testing SRP-1005, an experimental HTT-lowering drug for Huntington's disease. The trial aims to evaluate the safety and delivery method of SRP-1005, which is administered via subcutaneous injection. The study involves 32 participants and is expected to run through late 2027.

Sarepta Therapeutics rose 8.6% to $19.57 on Wednesday, driven by a broad biotech sector rally. Peer companies RXRX, TSHA, AGIO, DMRA, and SNDX also posted gains. The move reflects broader sector sentiment rather than company-specific news, with Sarepta's market cap now at $2.1 billion.

Sarepta Therapeutics reported Q2 2026 net product revenue of $328.7M, with GAAP operating income of $13.3M and non-GAAP operating income of $86.5M. The company appointed Michael Severino as CEO and narrowed its 2026 revenue guidance to $1.2B-$1.3B. Sarepta's pipeline includes treatments for Duchenne muscular dystrophy (DMD) and other rare diseases, with key data readouts expected in the second half of 2026. Analysts have mixed ratings and price targets for the company.

Simply Wall St reports Sarepta Therapeutics (SRPT) narrowed its 2026 total net product revenue guidance to $1.2b to $1.3b alongside Q2 results and pipeline updates. The article cites a consensus price target of $21.65 versus a $18.38 last close, with analyst targets ranging from $5.0 to $38.0, and notes ELEVIDYS safety and high R&D costs as risks.

Sarepta Therapeutics (SRPT) reported Q2 2026 results on an earnings call. Total revenue was $401.3M, down 34% YoY, with net product revenue $328.7M. Non-GAAP diluted EPS was $0.64. Cash and investments rose to $945.0M. 2026 product revenue guidance was narrowed to $1.2B-$1.3B, and Roche milestone and collaboration revenue were discussed.

State Street Corporation and affiliate SSGA Funds Management filed Schedule 13G disclosures for Sarepta Therapeutics. State Street reports 8,916,103 shares, 8.4% of the class, with shared voting power of 8,642,126 and shared dispositive power of 8,916,103. SSGA Funds Management reports 6,285,547 shares, 6%.

Sarepta Therapeutics reported GAAP and non-GAAP operating profitability and said ELEVIDYS commercial execution improved enrollment forms. It narrowed 2026 total net product revenue guidance to $1.2B-$1.3B and expects second-half revenue modestly lower. The company recorded a $39M litigation contingency and raised collaboration/other revenue guidance by $75M on higher Roche contract manufacturing. Interim MAD results for FSHD (SRP-1001) and DM1 (SRP-1003) are expected in H2 2026.

Sarepta Therapeutics appointed Michael Severino as CEO effective July 28, replacing Doug Ingram. The change comes as Elevidys faced FDA label restrictions tied to liver safety signals and Sarepta reported Q1 revenue of $730.8 million, down from about $745 million year over year, citing lower Elevidys volumes. FDA decision dates for Amondys 45 and Vyondys 53 are set for Feb. 28, 2027.

Sarepta Therapeutics (SRPT) reported Q2 2026 adjusted EPS of 64 cents vs 58 cents expected, though down 68% YoY. Revenues were $401.3M, down 34% YoY, beating the $355.6M estimate, mainly due to lower Elevidys sales. SRPT narrowed 2026 net product revenue guidance to $1.2-$1.3B and raised collaboration revenue to $550-$600M. FDA accepted filings for full approvals of Vyondys 53 and Amondys 45.